

**IN THE UNITED STATES DISTRICT  
COURT FOR THE NORTHERN DISTRICT OF  
ILLINOIS EASTERN DIVISION**

---

IN RE ABBOTT LABORATORIES INFANT  
FORMULA SHAREHOLDER  
DERIVATIVE LITIGATION

No. 1:22-cv-5513  
Hon. Sunil R. Harjani  
Hon. Laura K. McNally

---

**ORDER PRELIMINARILY APPROVING  
PROPOSED SETTLEMENT, DIRECTING THE ISSUANCE OF NOTICE, AND  
SETTING A FINAL SETTLEMENT HEARING**

---

WHEREAS, on March 17, 2026, the parties to the above-entitled action entered into a Stipulation and Agreement of Settlement (the “Stipulation”) that is subject to review under Rule 23.1 of the Federal Rules of Civil Procedure and that, together with the exhibits thereto, sets forth the terms and conditions for the proposed settlement of the claims alleged in this consolidated derivative action (the “Settlement”);

WHEREAS, the Court has reviewed and considered the Stipulation and the accompanying documents; and

WHEREAS, the parties to the Stipulation have consented to the entry of this order;

IT IS THEREFORE ORDERED as follows:

1. The Court hereby preliminarily approves the Stipulation and the Settlement set forth therein, subject to further consideration at the hearing described below, and preliminarily finds that the Settlement and terms of the Stipulation are fair, reasonable and adequate, and that for purposes of the Settlement, Lead Plaintiffs International Brotherhood of Teamsters Local No. 710 Pension Fund and Southeastern Pennsylvania Transportation Authority (“Lead Plaintiffs”) and their counsel, Cohen Milstein Sellers & Toll PLLC and Scott+Scott Attorneys at Law LLP (“Lead

Plaintiffs' Counsel"), fairly and adequately represent the interests of Abbott Laboratories ("Abbott") and Abbott Shareholders. All capitalized terms used in this Order have the meanings defined in the Stipulation unless otherwise defined herein.

2. A hearing shall be held before this Court on June 4, 2026 at 9:30 a.m. (the "Settlement Hearing") in Courtroom 1925 of the United States District Court for the Northern District of Illinois, 219 South Dearborn Street, Chicago, Illinois 60604, for purposes of considering:

- a. whether the proposed Settlement of the Consolidated Derivative Action, on the terms and conditions set forth in the Stipulation, should receive final approval by the Court as fair, reasonable, and adequate, and in the best interests of Abbott and Abbott Shareholders;
- b. any objections to the proposed Settlement;
- c. whether the Court should enter the proposed Final Order and Judgment;
- d. in the event the Settlement receives final approval as requested, to consider any application by Lead Plaintiffs' Counsel for an award of attorneys' fees, and reimbursement of expenses, including service awards for the Lead Plaintiffs; and
- e. such other matters as may be necessary or proper.

3. The Settlement Hearing may be continued or rescheduled without further notice to Abbott Shareholders. The Court further reserves the right to consider any modifications of the

Settlement agreed to by Lead Plaintiffs and Defendants without providing further written notice to Abbott Shareholders.

4. The Court approves the form, substance, and requirements of the Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear (the “Notice”), attached as Exhibit D to the Stipulation. The Court approves the form, substance, and requirements of the Summary Notice of Pendency of Shareholder Derivative Action Involving Abbott Laboratories, Proposed Settlement, and Settlement Hearing (the “Summary Notice”), attached as Exhibit E to the Stipulation.

5. Notice of the Settlement shall be published and disseminated to all current Abbott Shareholders and beneficial owners of Abbott stock as follows: (a) the Notice shall be filed by Abbott with the United States Securities and Exchange Commission in a Form 8-K no later than ten (10) business days following the date of this Order; (b) the Notice shall be maintained on the Investor Relations page of Abbott’s corporate website beginning within ten (10) business days from the date of this Order and until the date the Court enters Judgment approving the Settlement; and (c) the Summary Notice shall be published in Investor’s Business Daily or a similar online publication no later than ten (10) business days following the date of this Order. At or prior to the Settlement Hearing, Abbott shall file with the Court an affidavit indicating compliance with the requirements of this paragraph.

6. The Court hereby finds that the notice procedures described in paragraphs 4 and 5 above satisfy the requirements of the Federal Rules of Civil Procedure and due process, constitute reasonable notice under the circumstances, and shall constitute due and sufficient notice to Abbott Shareholders of the proposed Settlement and matters to be considered at the Settlement Hearing.

7. No later than May 7, 2026, Lead Plaintiffs' Counsel shall move for final approval of the Settlement and may petition the Court for an award of attorneys' fees and reimbursement of expenses, including service awards for the Lead Plaintiffs.

8. The Court will consider any written objections to the proposed Settlement or the application for attorneys' fees and reimbursement of expenses, including service awards for the Lead Plaintiffs, at the Settlement Hearing, but only if such objections, and any supporting papers, are mailed to each of the following, TO BE RECEIVED NOT LATER THAN May 18, 2026:

**Court:**

Clerk of the Court  
United States District Court for the Northern District of Illinois  
219 South Dearborn Street  
Chicago, IL 60604

**Lead Plaintiffs' Counsel:**

Carol V. Gilden  
COHEN MILSTEIN SELLERS & TOLL PLLC  
200 S. Wacker Drive, Suite 2375  
Chicago, Illinois 60606

Justin O. Reliford  
SCOTT+SCOTT  
ATTORNEYS AT LAW LLP  
222 Delaware Avenue, Suite 1405  
Wilmington, DE 19801

**Abbott's Counsel:**

Eric R. Swibel  
LATHAM & WATKINS LLP  
330 N. Wabash Ave., Suite 2800  
Chicago, Illinois 60611

**Individual Defendants' Counsel:**

Brenton A. Rogers  
KIRKLAND & ELLIS LLP  
333 West Wolf Point Plaza  
Chicago, Illinois 60654

Written objections must provide a detailed signed statement of the objector's specific objections, and must include all documents such person wishes the Court to consider, as well as a statement specifying the objector's name, address, telephone number, the number of shares of Abbott common stock currently owned, and the most recently available account statement evidencing such ownership.

9. Any Abbott Shareholder may appear at the Settlement Hearing, in person or through counsel of his or her choice, to object and show cause why: (i) the Settlement as set forth in the Stipulation should not be approved; (ii) the proposed Final Order and Judgment should not be entered; or (iii) the Court should not award Lead Plaintiffs' Counsel attorneys' fees and reimbursement of expenses, including service awards for the Lead Plaintiffs, in the amounts sought by Lead Plaintiffs' Counsel; provided, however, that no person shall be entitled to appear or be heard, or be entitled to object to or otherwise contest any of the matters to be considered at the Settlement Hearing, unless such person has: (i) filed with or mailed to the Clerk of the Court, and (ii) served by hand, by first class U.S. mail, postage prepaid, or by reputable express carrier on the Clerk of the Court and each of the counsel listed in paragraph 8 above, the following materials, TO BE RECEIVED no later than May 18, 2026: (i) a notice of intention to appear at the Settlement Hearing; (ii) a statement specifying that person's name, address, telephone number, the number of shares of Abbott common stock currently owned, and the most recently available brokerage account statement evidencing such ownership; (iii) the name(s) of any attorney that will appear on the person's behalf; and (iv) a statement of such person's position with respect to the Settlement, providing all supporting bases and reasons for the objection, including the identification of all witnesses, documents or other evidence that are to be presented at the Settlement Hearing in

connection with the objection and a summary of the substance of the testimony to be given by any such witnesses.

10. Any Abbott Shareholder who does not timely file and serve an objection in the manner provided in paragraphs 8 and 9 of this Order shall be deemed to have waived any objection such person might have and shall forever be barred, in these proceedings or in any other proceeding, from making any objection to or otherwise challenging the Settlement of the Consolidated Derivative Action, the Stipulation or any provision thereof, the Final Order and Judgment, the application and award of attorneys' fees and reimbursement of expenses, including service awards for the Lead Plaintiffs, and/or any other proceedings herein, and shall have no right to appeal therefrom.

11. The Settling Parties shall submit their papers in response to any objections to the Settlement by no later than May 28, 2026.

12. Pending final determination of whether the proposed Settlement should be approved or further order of this Court, the Releasing Parties are barred and enjoined from commencing, prosecuting, instigating, continuing, or in any way participating in the commencement or prosecution of any action asserting any Released Claims against any of the Released Parties or challenging the Settlement other than in this action in accordance with the procedures established by the Court.

13. Regardless of whether or not the Settlement is approved, the fact of and provisions contained in the Stipulation (including any Exhibits thereto), the Settlement, and all negotiations, drafts, discussions, actions and proceedings in connection with the Stipulation or the Settlement shall not be deemed or constitute a presumption, concession, or an admission by any Settling Party in the Consolidated Derivative Action, any signatory to the Stipulation, or any Released Party of

any fault, liability, or wrongdoing as to any facts or claims alleged or asserted in the Consolidated Derivative Action, the Additional Derivative Actions, or any other actions or proceedings, and shall not be interpreted, construed, deemed, involved, invoked, offered or received in evidence or otherwise used by any person in the Consolidated Derivative Action, the Additional Derivative Actions, or in any other action or proceeding, whether civil, criminal or administrative; provided, however, that nothing herein shall prevent the introduction into evidence of the Stipulation or this Order in connection with any proceeding to enforce the terms of the Stipulation or this Order, including but not limited to the filing of the Stipulation and/or this Order by any Released Party in order to prevent or terminate institution, commencement or prosecution of any action which asserts Released Claims against any of the Released Parties.

14. In the event that a termination and cancellation of the Settlement occurs pursuant to terms of the Stipulation: (i) the terms and provisions of the Stipulation shall be rendered void and shall have no further force and effect, except as otherwise provided in the Stipulation; and (ii) the Settling Parties shall be deemed to have reverted to their positions as of immediately prior to the execution of the Stipulation.

Dated: April 10, 2026

A handwritten signature in cursive script, reading "Sunil R. Harjani", is written above a horizontal line.

The Honorable Sunil R. Harjani